Supernus Pharmaceuticals (NASDAQ:SUPN) Raised to “Strong-Buy” at StockNews.com

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) was upgraded by investment analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.

Separately, Piper Sandler cut their price objective on Supernus Pharmaceuticals from $38.00 to $36.00 in a report on Tuesday, October 11th.

Supernus Pharmaceuticals Stock Up 0.2 %

Shares of SUPN opened at $38.74 on Friday. The stock has a market capitalization of $2.09 billion, a P/E ratio of 60.53 and a beta of 0.94. Supernus Pharmaceuticals has a twelve month low of $24.95 and a twelve month high of $39.92. The company has a 50 day moving average of $36.05 and a 200-day moving average of $33.80.

Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last issued its quarterly earnings results on Tuesday, November 8th. The specialty pharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.29). The business had revenue of $177.35 million for the quarter, compared to the consensus estimate of $173.22 million. Supernus Pharmaceuticals had a return on equity of 4.51% and a net margin of 5.72%. On average, sell-side analysts anticipate that Supernus Pharmaceuticals will post 1.63 earnings per share for the current fiscal year.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, CEO Jack A. Khattar sold 1,115 shares of the firm’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $35.00, for a total transaction of $39,025.00. Following the completion of the sale, the chief executive officer now owns 780,742 shares of the company’s stock, valued at approximately $27,325,970. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, VP Padmanabh P. Bhatt sold 6,800 shares of the firm’s stock in a transaction on Friday, November 11th. The stock was sold at an average price of $34.95, for a total value of $237,660.00. Following the transaction, the vice president now owns 1,644 shares in the company, valued at $57,457.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jack A. Khattar sold 1,115 shares of the firm’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $35.00, for a total value of $39,025.00. Following the completion of the transaction, the chief executive officer now owns 780,742 shares in the company, valued at approximately $27,325,970. The disclosure for this sale can be found here. Insiders sold 39,068 shares of company stock valued at $1,418,046 in the last quarter. 8.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Strs Ohio bought a new position in Supernus Pharmaceuticals in the third quarter valued at about $27,000. First Horizon Advisors Inc. acquired a new position in shares of Supernus Pharmaceuticals in the second quarter worth approximately $34,000. Public Employees Retirement System of Ohio lifted its stake in Supernus Pharmaceuticals by 41.6% in the third quarter. Public Employees Retirement System of Ohio now owns 1,253 shares of the specialty pharmaceutical company’s stock valued at $42,000 after buying an additional 368 shares during the period. Quantbot Technologies LP acquired a new position in Supernus Pharmaceuticals in the third quarter valued at approximately $57,000. Finally, Altshuler Shaham Ltd acquired a new position in Supernus Pharmaceuticals in the third quarter valued at approximately $59,000. Institutional investors own 99.82% of the company’s stock.

About Supernus Pharmaceuticals

(Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.